阅读说明：本技术 一种n-乙酰基氧氟沙星的丙烯酮衍生物及其制备方法和应用 (Propenone derivative of N-acetylofloxacin and preparation method and application thereof ) 是由 胡国强 张芳 于 2019-11-20 设计创作，主要内容包括：本发明公开了一种N-乙酰基氧氟沙星的丙烯酮衍生物及其制备方法和应用,采用如下式Ⅰ化学结构通式：式I中,芳香环Ar为苯环或取代苯环或呋喃环或吡啶环。本发明的一种N-乙酰基氧氟沙星的丙烯酮衍生物,实现了氟喹啉酮骨架与丙烯酮骨架的有效拼合,进而构筑了新的氟喹诺酮“类查尔酮”化合物,从而增加了新化合物的抗肿瘤活性及抗耐药性,并降低对正常细胞的毒副作用,可以作为抗肿瘤活性物质开发全新结构的抗肿瘤药物。(The invention discloses an acrylketone derivative of N-acetylofloxacin, a preparation method and application thereof, wherein the chemical structural general formula of the formula I is as follows:)

1. The propenone derivative of the N-acetylofloxacin is characterized by being a typical compound with the following structure:

2. the preparation method of the propenone derivative of N-acetylofloxacin according to claim 1, which comprises the following steps:

1) taking N-acetylofloxacin shown as a formula II as a raw material, reacting with Carbonyldiimidazole (CDI) to prepare an N-acetylofloxacin imidazole amide compound shown as a formula III, and then carrying out condensation reaction with monoethyl malonate potassium salt to prepare a C-3 formyl ethyl acetate compound of the N-acetylofloxacin shown as a formula IV; finally, the N-acetylofloxacin C-3 ethanone shown in the formula V is prepared by the hydrolysis decarboxylation reaction of the formula IV:

2) the propenone derivative of N-acetylofloxacin as shown in claim 1 can be prepared by the following steps of carrying out Claisen-Schmidt condensation reaction on N-acetylofloxacin C-3 ethanone shown in formula V and aromatic aldehyde under the catalysis of alkali to form an propenone structure, and carrying out post-treatment.

3. The method for preparing the propenone derivative of N-acetylofloxacin according to claim 2, wherein the molar ratio of N-acetylofloxacin shown as formula II to CDI is 1: 1.0-2.0, the molar ratio of N-acetylofloxacin imidazole amide shown as formula III to monoethyl malonate potassium salt is 1: 1.0-1.5, and the molar ratio of N-acetylofloxacin-3 ethanone shown as formula V to aromatic aldehyde is 1: 1.0-2.0.

4. The use of the propenone derivative of N-acetylofloxacin as defined in claim 1 in the preparation of anti-tumor drugs.

5. The use of the propenone derivative of N-acetylofloxacin according to claim 4 for preparing an antitumor medicament, wherein the antitumor medicament is a medicament for treating human non-small cell lung cancer, kidney cancer, liver cancer, stomach cancer, pancreatic cancer or leukemia.

Technical Field

The invention belongs to the technical field of innovative medicine synthesis, and particularly relates to an acrylketone derivative of N-acetylofloxacin, a preparation method of the acrylketone derivative of the N-acetylofloxacin, and application of the acrylketone derivative of the N-acetylofloxacin in antitumor medicines.

Background

New drug innovation stems from the discovery of leads, and rational drug molecular design based on structure or mechanism is an effective method for discovering leads. In the drug effect groups with various structures, the acrylketone structure is not only the characteristic structure of a chalcone compound which is a natural effective component, but also the characteristic drug effect group of a targeted antitumor drug sunitinib. Therefore, compounds constructed with acrylketone as a structural fragment and having various pharmacological activities have been attracting attention. However, most of natural chalcone compounds are multi-hydroxyl benzene ring substituted propenone compounds, and the poor water solubility of the compounds causes low bioavailability and limits clinical application. In addition, the topoisomerase which is an action target point of the antibacterial fluoroquinolone medicine is also an important action target point of the antitumor medicine, the antibacterial activity of the antibacterial fluoroquinolone medicine can be converted into the antitumor activity, and the fluoroquinolone C-3 carboxyl is not a pharmacophore required by the antitumor activity and can be replaced by a biological electron isostere to improve the antitumor activity of the fluoroquinolone medicine. However, the research on the replacement of the C-3 carboxyl group of fluoroquinolone with aryl acrylketone has not been reported. Based on the above, in order to improve the water solubility of chalcone, hydrophilic piperazinyl is introduced to increase the water solubility and improve the bioavailability and the biological activity of the chalcone, the invention uses the skeleton of the advantageous pharmacophore 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one of the fluoroquinolone drug N-acetylofloxacin as a substituent of an aryl propenone structure, and further designs the novel fluoroquinolone chalcone derivatives.

Therefore, the invention aims to provide the propenone derivative of the N-acetylofloxacin, which has the function and the effect of resisting tumors and simultaneously provides a preparation method of the propenone derivative of the N-acetylofloxacin.

In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: the acrylketone derivative of N-acetylofloxacin has a chemical structural formula shown as a general formula I:

in the formula I, Ar is a benzene ring or a substituted benzene ring or a furan ring or a pyridine ring, and the compound is a compound with the following specific structure:

the preparation method of the acrylketone derivative of N-acetylofloxacin of the invention is prepared by taking commercially obtained N-acetylofloxacin shown as a formula II as a raw material;

the preparation method comprises the following specific steps:

1) the preparation method of the N-acetylofloxacin imidazole amide compound shown as the formula III is characterized in that the commercially obtained N-acetylofloxacin shown as the formula II is used as a raw material and reacts with Carbonyldiimidazole (CDI), and the specific preparation method is as follows:

23.0g (60.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-carboxylic acid II is dissolved in 500mL of anhydrous acetonitrile, 15.2g (94.0mmol) of carbonyldiimidazole is added, and the reaction mixture is stirred in a water bath and refluxed until the starting material II disappears. Standing at room temperature, filtering and collecting generated solid, and recrystallizing with acetone to obtain the N-acetylofloxacin imidazole amide light yellow crystal shown as the formula III, wherein the yield is 81.4%, and the m.p.236-238 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.67(3H,d,CH₃),2.38(3H,s,COH₃) 3.15 to 3.78(8H, m, piperazine-H), 4.46 to 4.86(3H, m, O-CH)₂CH-N), 7.48-7.76 (2H, m, imidazole-H), 8.16(1H, s, imidazole-H), 8.94(1H, d, 5-H),9.15(1H, s, 2-H); MS (m/z): 440[ M + H ]]⁺Calculating (C)₂₂H₂₂FN₅O₄)：439.45。

As a further improvement, the molar ratio of the N-acetylofloxacin shown as the formula II to the carbonyldiimidazole is 1: 1.0-2.0, and the solvent can be at least one of acetonitrile, tetrahydrofuran, dioxane and dimethylformamide or a mixed solvent of the two.

2) The N-acetylofloxacin imidazole amide shown in the formula III and monoethyl malonate potassium salt are subjected to condensation reaction under the catalysis of triethylamine-magnesium chloride to prepare the C-3 formyl ethyl acetate compound of the N-acetylofloxacin shown in the formula IV, and the specific preparation method is as follows:

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (1H-imidazole-1-formyl) - [ quinolin-4 (1H) -one, 17.0g (39.0mmol) of formula III, 6.6g (69.1mmol) of magnesium chloride and 8.3g (49.0mmol) of potassium monoethyl malonate were sequentially added to 600mL of anhydrous acetonitrile, 12.2g (12.0mmol) of triethylamine was added dropwise with stirring in an ice bath, and the mixture was stirred in a water bath and refluxed until the raw material III disappeared. The solvent was evaporated under reduced pressure, 500mL of water was added, the mixture was extracted with methylene chloride (3X 150mL), the organic phases were combined, washed with water (3X 200mL), washed with saturated brine (2X 150mL), and dried over anhydrous sodium sulfate. And recovering dichloromethane at normal pressure, and recrystallizing the residue with absolute ethyl alcohol to obtain a white crystal shown as a formula IV, wherein the yield is 77.6%, and m.p.232-234 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.27～1.67(6H，m，2×CH₃)，2.38(3H,s,COH₃) 3.15 to 3.75(8H, m, piperazine-H), 3.46 to 4.86(7H, m, COCH)₂COOCH₂And O-CH₂CH-N)，8.96(1H，d，5-H)，9.15(1H，s,2-H)；MS(m/z)：460[M+H]⁺Calculating (C)₂₃H₂₆FN₃O₆)：459.48。

3) The C-3 ethyl formylacetate compound of the N-acetylofloxacin shown in the formula IV is hydrolyzed and decarboxylated by using 6 percent of sodium hydroxide aqueous solution by mass fraction, so as to conveniently prepare the C-3 ethanone compound of the N-acetylofloxacin shown in the formula V, and the specific preparation method is as follows:

taking 10g (22.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-formylacetic acid ethyl ester formula IV and suspending the ethyl ester in 200mL of sodium hydroxide aqueous solution with the mass fraction of 3%, stirring in an oil bath and refluxing to react until the raw material IV disappears. Standing at room temperature, filtering to collect the generated solid, washing with water to be neutral, drying, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal of formula V, wherein the yield is 85.4%, and m.p.234-236 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.67(3H,d,CH₃),2.38,2.42(6H，2s，2×COCH₃) 3.16 to 3.78(8H, m, piperazine-H), 4.46 to 4.86(3H, m, O-CH)₂CH-N)，8.97(1H，d，5-H)，9.16(1H，s,2-H)；MS(m/z)：388[M+H]⁺Calculating (C)₂₀H₂₂FN₃O₄)：387.41。

4) C-3 ethanone of the N-acetylofloxacin shown in the formula V and aromatic aldehyde are subjected to Claisen-Schmidt aldol condensation reaction in absolute ethyl alcohol under the catalysis of alkali, and after the reaction is completed, a target compound is obtained through treatment, wherein the target compound is shown in the formula I, and the specific process is as follows:

wherein Ar in the formula I is a benzene ring or a substituted benzene ring or a furan ring or a pyridine ring.

The general synthetic preparation procedure for the target compound of formula i is: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and an aromatic aldehyde (3.0mmol) and a base catalyst piperidine (0.1mL) were added. And (3) refluxing and reacting the mixed reactants for 15-24 h, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal shown in the formula I.

As a further improvement, the mol ratio of the N-acetylofloxacin C-3 ethanone shown in the formula V to the aromatic aldehyde is 1: 1.0-1.5.

The base catalyst is at least one of piperidine, pyridine, triethylamine, morpholine, potassium acetate, sodium hydroxide ethanol solution or potassium hydroxide ethanol solution.

The application of the acrylketone derivative of the N-acetylofloxacin in preparing the antitumor drugs.

The anti-tumor drug is a drug for treating human non-small cell lung cancer, kidney cancer, liver cancer, stomach cancer, pancreatic cancer or leukemia.

The acrylketone derivative of the N-acetylofloxacin is designed and synthesized by effectively combining a fluoroquinolone framework and an aryl acrylketone pharmacophore based on the split principle of the pharmacophores, realizes the complementation and the activity superposition of the pharmacophores with different structures, achieves the effects of synergy, toxicity reduction and drug resistance, and can be developed as an anti-tumor drug with a brand new structure.

Detailed Description

Example 1

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3-cinnamoyl-quinolin-4 (1H) -one (I-1) having the chemical formula:

namely, Ar in the formula I is phenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.40g (3.8mmol) of benzaldehyde and piperidine, a basic catalyst (0.1mL) were added. And (3) refluxing and reacting the mixed reactants for 18h, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-1, wherein the yield is 82.4%, and the m.p.234-236 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.67(3H,d,CH₃),2.38(3H，s，COCH₃) 3.16 to 3.78(8H, m, piperazine-H), 4.46 to 4.86(3H, m, O-CH)₂CH-N)，7.64～8.76(7H，m，Ph-H, 3 '-H, and 2' -H), 8.96(1H, d, 5-H),9.15(1H, s, 2-H); MS (m/z): 476[ M + H ]]⁺Calculating (C)₂₇H₂₆FN₃O₄)：475.52。

Example 2

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (4-methoxycinnamoyl) -quinolin-4 (1H) -one (I-2) having the chemical formula:

namely, Ar in the formula I is p-methoxyphenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.57g (4.2mmol) of 4-methoxybenzaldehyde and piperidine, a basic catalyst (0.1mL) were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-2, wherein the yield is 83.6%, and the m.p.236-238 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.67(3H,d,CH₃),2.38(3H，s，COCH₃) 3.17 to 3.76(8H, m, piperazine-H), 3.92(3H, s, OCH)₃)，4.47～4.86(3H，m，O-CH₂CH-N), 7.64-8.87 (6H, m, Ph-H, 3 '-H and 2' -H), 8.97(1H, d, 5-H),9.16(1H, s, 2-H); MS (m/z): 506[ M + H]⁺Calculating (C)₂₈H₂₈FN₃O₅)：505.55。

Example 3

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (3, 4-dioxocinnamoyl) -quinolin-4 (1H) -one (I-3) having the chemical formula:

namely, Ar in the formula I is 3,4- (dioxymethylene) phenyl.

The preparation method of the compoundComprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.53g (3.5mmol) of 3, 4-dioxytolualdehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-3, wherein the yield is 85.7%, and the m.p.245-247 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.67(3H,d,CH₃),2.38(3H，s，COCH₃) 3.15 to 3.78(8H, m, piperazine-H), 4.46 to 4.86(3H, m, O-CH)₂CH-N)，6.24(2H，s，OCH₂O), 7.65-8.86 (5H, m, Ph-H, 3 '-H and 2' -H), 8.95(1H, d, 5-H),9.16(1H, s, 2-H); MS (m/z): 520[ M + H ]]⁺Calculating (C)₂₈H₂₆FN₃O₆)：519.53。

Example 4

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (3,4, 5-trimethoxycinnamoyl) -quinolin-4 (1H) -one (I-4) having the chemical formula:

namely, Ar in the formula I is 3,4, 5-trimethoxyphenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.63g (3.2mmol) of 3,4, 5-trioxybenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) refluxing and reacting the mixed reactants for 20 hours, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-4, wherein the yield is 76.2%, and the m.p.232-234 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.67(3H,d,CH₃),2.38(3H，s，COCH₃) 3.15 to 3.85(8H, m, piperazine-H), 3.88,3.93(9H, 2s,3 XOCH)₃)，4.46～4.86(3H，m，O-CH₂CH-N), 7.64-8.87 (4H, m, Ph-H, 3 '-H and 2' -H), 8.97(1H, d, 5-H),9.15(1H, s, 2-H); MS (m/z): 566[ M + H]⁺Calculating (C)₃₀H₃₂FN₃O₇)：565.60。

Example 5

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (4-methylcinnamoyl) -quinolin-4 (1H) -one (I-5) having the chemical formula:

namely, Ar in the formula I is p-methyl-phenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.58g (4.8mmol) of 4-methylbenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 15h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-5, wherein the yield is 72.5%, and m.p.230-232 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.66(3H,d,CH₃),2.28(3H，s，Ph-CH₃)，2.37(3H，s，COCH₃) 3.13 to 3.76(8H, m, piperazine-H), 4.46 to 4.85(3H, m, O-CH)₂CH-N), 7.64-8.86 (6H, m, Ph-H, 3 '-H and 2' -H), 8.94(1H, d, 5-H),9.08(1H, s, 2-H); MS (m/z): 490[ M + H [ ]]⁺Calculating (C)₂₈H₂₈FN₃O₄)：489.55。

Example 6

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (4-fluorocinnamoyl) -quinolin-4 (1H) -one (I-6) having the chemical formula:

namely, Ar in the formula I is p-fluoro-phenyl.

The preparation method of the compound comprises the following steps: 1.0g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V is dissolved in 20mL of anhydrous ethanol,0.48g (3.8mmol) of 4-fluorobenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 15h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-6, wherein the yield is 85.6%, and the m.p.242-244 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.70(3H,d,CH₃),2.40(3H，s，COCH₃) 3.20 to 3.87(8H, m, piperazine-H), 4.48 to 4.95(3H, m, O-CH)₂CH-N), 7.66-8.95 (6H, m, Ph-H, 3 '-H and 2' -H), 9.05(1H, d, 5-H),9.17(1H, s, 2-H); MS (m/z): 494[ M + H]⁺Calculating (C)₂₇H₂₅F₂N₃O₄)：493.51。

Example 7

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (4-chlorocinnamoyl) -quinolin-4 (1H) -one (I-7) having the chemical formula:

namely, Ar in the formula I is p-chlorophenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.45g (3.2mmol) of 4-chlorobenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-7, wherein the yield is 81.7%, and the m.p.237-239 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.68(3H,d,CH₃),2.40(3H，s，COCH₃) 3.16 to 3.87(8H, m, piperazine-H), 4.46 to 4.88(3H, m, O-CH)₂CH-N), 7.66-8.92 (6H, m, Ph-H, 3 '-H and 2' -H), 9.05(1H, d, 5-H),9.16(1H, s, 2-H); MS (m/z): 510[ M + H]⁺Calculating (C)₂₇H₂₅FClN₃O₄)：509.97。

Example 8

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (4-bromocinnamoyl) -quinolin-4 (1H) -one (I-8) having the chemical formula:

namely, Ar in the formula I is p-bromophenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.67g (3.6mmol) of 4-bromobenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 24 hours, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a light yellow crystal, namely a formula I-8, wherein the yield is 82.5%, and the m.p.243-245 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.68(3H,d,CH₃),2.42(3H，s，COCH₃) 3.17 to 3.85(8H, m, piperazine-H), 4.48 to 4.87(3H, m, O-CH)₂CH-N), 7.66-8.97 (6H, m, Ph-H, 3 '-H, and 2' -H), 9.05(1H, d, 5-H),9.15(1H, s, 2-H); MS (m/z): 554 and 556[ M + H]⁺(⁷⁹Br and⁸¹br), calculating (C)₂₇H₂₅FBrN₃O₄)：554.42。

Example 9

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (4-nitrocinnamoyl) -quinolin-4 (1H) -one (I-9) having the chemical formula:

namely, Ar in the formula I is p-nitrophenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.54g (3.6mmol) of 4-nitrobenzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 24 hours, standing at room temperature, filtering and collecting the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal, namely the formula I-9, wherein the yield is 78.6%, and the m.p.246-248 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.70(3H,d,CH₃),2.42(3H，s，COCH₃) 3.25 to 3.96(8H, m, piperazine-H), 4.48 to 4.97(3H, m, O-CH)₂CH-N), 7.67-9.06 (6H, m, Ph-H, 3 '-H and 2' -H), 9.13(1H, d, 5-H),9.21(1H, s, 2-H); MS (m/z): 521[ M + H]⁺Calculating (C)₂₇H₂₅FN₄O₆)：520.52。

Example 10

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- (4-hydroxy-cinnamoyl) -quinolin-4 (1H) -one (I-10) having the chemical formula:

namely, Ar in the formula I is 4-hydroxy-phenyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.49g (4.0mmol) of 4-hydroxy-benzaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 20h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal, namely a formula I-10, wherein the yield is 78.5%, and the m.p.232-234 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.67(3H,d,CH₃),2.40(3H，s，COCH₃) 3.15 to 3.85(8H, m, piperazine-H), 4.46 to 4.86(3H, m, O-CH)₂CH-N), 7.64-8.87 (6H, m, Ph-H, 3 '-H and 2' -H), 8.93(1H, d, 5-H),9.15(1H, s,2-H), 10.68(1H, s, OH); MS (m/z): 492, calculate (C)₂₇H₂₆FN₃O₅)：491.52。

Example 11

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- [3- (pyridin-3-yl) acryloyl ] -quinolin-4 (1H) -one (I-11) having the chemical formula:

namely, Ar in the formula I is 3-pyridyl.

The preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.37g (3.6mmol) of 3-pyridylaldehyde and piperidine (0.1mL) as a base catalyst were added. And (3) carrying out reflux reaction on the mixed reactants for 15h, standing at room temperature, filtering to collect the generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal, namely a formula I-11, wherein the yield is 83.1%, and the m.p.248-250 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.72(3H,d,CH₃),2.44(3H，s，COCH₃) 3.36 to 3.91(8H, m, piperazine-H), 4.48 to 4.97(3H, m, O-CH)₂CH-N), 7.67(1H, d, 2 '-H), 8.87-9.16 (6H, 5-H, 3' -H and pyridine-H), 9.24(1H, s, 2-H); MS (m/z): 477 calculating (C)₂₅H₂₅FN₄O₄)：476.51。

Example 12

1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -3- [3- (furan-2-yl) acryloyl ] quinolin-4 (1H) -one (I-12) having the chemical formula:

namely, Ar in the formula I is 2-furyl.

The preparation method of the compound comprises the following steps: the preparation method of the compound comprises the following steps: 1.2g (3.0mmol) of 1, 8-isopropoxy-6-fluoro-7- (4-acetylpiperazin-1-yl) -quinolin-4 (1H) -one-3-ethanone V was dissolved in 20mL of anhydrous ethanol, and 0.38g (4.0mmol) of 2-furfural and piperidine (0.1mL) as a base catalyst were added. And (3) refluxing and reacting the mixed reactants for 18h, standing at room temperature, filtering and collecting generated solid, and recrystallizing with absolute ethyl alcohol to obtain a yellow crystal, namely a formula I-12, wherein the yield is 78.6%, and the m.p.246-248 ℃.¹H NMR(400MHz,CD₃Cl)δ：1.68(3H,d,CH₃),2.40(3H，s，COCH₃) 3.18 to 3.86(8H, m, piperazine-H), 4.48 to 4.91(3H, m, O-CH)₂CH-N), 7.42 to 8.26(5H, m, 2 '-H, 3' -H and furan-H), 8.97(1H, d, 5-H),9.15(1H, s,2-H)；MS(m/z)：466[M+H]⁺Calculating (C)₂₅H₂₄FN₃O₅S)：465.49。

Test examples

Examples 1-12 measurement of antitumor Activity in vitro of acrylketone derivative of N-acetylofloxacin

1. Test sample

15 of the propenone derivatives of N-acetylofloxacin provided in examples 1-12, the classical antitumor TOPO inhibitor 10-Hydroxycamptothecin (HC), the chalcone tyrosinase inhibitor Sunitinib (SN), the broad-spectrum anticancer drug Doxorubicin (DOX), and the parent compound ofloxacin (AOF) were used as test samples, wherein HC, SN, and AOF are used as control groups, and examples 1-12 are used as test groups;

thiazole blue (MTT), HC, SN and AOF are all products of Sigma company; the RPMI-1640 culture solution is a product of GIBCO company; other used reagents are all domestic analytical pure reagents.

The experimental cancer cell strains are respectively a human non-small cell lung cancer cell strain A549, a human kidney cancer cell strain 769-P, a human hepatoma cell strain Hep-3B, a human gastric cancer cell strain HGC27, a human pancreatic cancer cell strain Panc-1 and a human leukemia cell strain HL60, which are purchased from Shanghai cell banks of Chinese academy of sciences. The human renal clear cell carcinoma cell sunitinib-resistant strain 7SuR was purchased from shanghai zel biotechnology limited, and the normal cell was obtained from african green monkey kidney cell line VERO and purchased from shanghai tong biology limited.

2. Measurement method

The determination method comprises the following specific steps:

1) firstly, the 15 samples were dissolved in dimethyl sulfoxide (DMSO) to prepare 1.0X 10^{- 4}mol·L^-1Stock solution of concentration, then diluting the stock solution with 10% calf serum RPMI-1640 culture solution to have 5 concentration gradients (0.1, 1.0, 5.0, 10.0, 50.0 μmol. L)^-1) The working fluid of (1);

2) collecting non-small cell lung cancer cell strain A549, human renal cancer cell strain 769-P, and human liver cancer cell in logarithmic growth phaseStrain Hep-3B, human gastric cancer cell line HGC27, human pancreatic cancer cell line Panc-1, human leukemia cell line HL60, human renal clear cell carcinoma cell sunitinib drug-resistant strain 7SuR and African green monkey kidney cell line VERO, 6000 cells per well were inoculated into a 96-well plate, then working solutions with 5 concentration gradients of the above 15 samples were added, 5 g.L.was added to each well after 48 hours^–1mu.L of MTT (thiazole blue) solution was added, and after further culturing for 4 hours, 100. mu.L of a 10% by mass Sodium Dodecyl Sulfate (SDS) solution was added. Culturing for 24 hours, and then measuring an absorbance (OD) value at a wavelength of 570nm by using a microplate reader;

3) the inhibition rate of the test samples with different concentrations on the cancer cells is calculated according to the following formula:

cancer cell inhibition rate ═ [ (1-experimental OD value)/control OD value ] × 100%;

then, linear regression is carried out on the cancer cell inhibition rate corresponding to each concentration by the pair value of each concentration of the test sample to obtain a dose-effect equation, and the half Inhibition Concentration (IC) of the test sample to the experimental cancer cell is calculated from the obtained dose-effect equation₅₀) (ii) a Each data was measured in triplicate and averaged, the results are shown in Table 1.

TABLE 1 antitumor Activity (IC) of the test samples₅₀)

As can be seen from Table 1, the inhibitory activity of the compounds provided in examples 1-12 on 7 cancer cells of experiment is significantly stronger than that of the parent compound N-acetylofloxacin, especially the growth inhibitory activity of some compounds on human non-small cell lung cancer cell line A549 is stronger than that of the control Hydroxycamptothecin (HC), tyrosine kinase inhibitors Sunitinib (SN) and adriamycin (DOX), and the IC of the compounds is₅₀The value is reached or close to nanomolar concentration, and the method has the value of new drug development. More significantly, the compounds provided in examples 1-12 also showed very strong sensitivity to sunitinib-resistant strain 7SuR, showed strong drug-resistant activity, and showed good cell response to VEROLow cytotoxicity and property of becoming drug. Therefore, according to the general approach of drug development, the conventional antitumor in vitro screening is carried out, and then the targeted research is carried out, so that the compound has strong antitumor activity, drug resistance activity and lower cytotoxicity, and can be used for preparing antitumor drugs by salifying with acid acceptable for human bodies or mixing with medicinal carriers.